Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
The Netherlands Cancer Institute
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
Bristol-Myers Squibb
Hackensack Meridian Health
Gazi University
H. Lee Moffitt Cancer Center and Research Institute
Washington University School of Medicine
Big Ten Cancer Research Consortium
Dana-Farber Cancer Institute
University Health Network, Toronto
Bristol-Myers Squibb
Brown University
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Bristol-Myers Squibb
ImmunityBio, Inc.
Duke University
7 Hills Pharma, LLC
Vyriad, Inc.
University of Alabama at Birmingham
TCR2 Therapeutics
Incyte Corporation
Iovance Biotherapeutics, Inc.
Bristol-Myers Squibb
GlaxoSmithKline
The First Affiliated Hospital of Guangzhou Medical University
Fundación GECP
Inspirna, Inc.
M.D. Anderson Cancer Center
Agenus Inc.
Vanderbilt-Ingram Cancer Center
Second Affiliated Hospital of Guangzhou Medical University
Xencor, Inc.
Bristol-Myers Squibb
Persephone Biosciences
Bristol-Myers Squibb
Lung Cancer Group Cologne
Bristol-Myers Squibb
Fondazione per la Medicina Personalizzata
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Gritstone bio, Inc.
Gritstone bio, Inc.
Assistance Publique Hopitaux De Marseille
Bristol-Myers Squibb